Cocrystal Pharma Inc (COCP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.130.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · COCP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -18.2% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
COCP — capital allocation — The sale of shares was exempt from registration
Dated 2026-08-03
The sale of shares was exempt from registration based upon Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D promulgated thereunder. The Purchaser is an accredited investor and acquired the shares for investment.
Why it matters: A new CEO can change company strategy. Clear direction can impact future growth.
Watch forCEO outlines a clear and positive strategic plan in the next earnings call.
Also watch forCEO fails to provide a clear strategy or faces immediate challenges.
Why it matters: Sector challenges could hurt the company's growth and how investors feel.
Worry ifThe Health Care sector shows signs of revenue growth above 10 percent.
Less concerning ifOngoing slow growth in the sector or worsening challenges.
Why it matters: This data is crucial for Cocrystal's lead drug, CDI-988. Positive results could boost investor confidence.
Supportive ifThe main results from the Phase 1b norovirus trial show good effectiveness.
Worry ifThe main results show low effectiveness. There are also safety problems.
Why it matters: Maintaining financial discipline is crucial to manage losses. Progress can improve cash flow.
Supportive ifOperating losses are lower. This shows better cash management.
Worry ifOperating losses go up or cash use worsens, showing bad financial control.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$192 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $639 loss on $10,000 · 6.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,810 loss on $10,000 · 48.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Better financial discipline may show better management. This could help the company later.
Supportive ifOperating losses decrease further from -$2.36M in 2026-Q1 to below -$2M.
Worry ifOperating losses grow or stay the same. This shows poor financial management.
Why it matters: Good results would show Cocrystal can help treat norovirus. This is a big need.
Supportive ifCDI-988 shows a significant reduction in clinical symptoms in the Phase 1b study.
Worry ifCDI-988 does not show a real drop in symptoms. Safety issues may come up.
Why it matters: Progress in clinical trials is key for Cocrystal's growth. It shows if their drugs are effective.
Supportive ifLook for news about good results or progress in antiviral drug trials.
Worry ifWatch for news of delays or bad results in antiviral drug trials.
Why it matters: The new CEO's direction can change Cocrystal's strategy and performance. This could affect investor confidence.
Watch forThe new CEO shares a plan that includes new partnerships and initiatives.
Also watch forThe new CEO fails to outline a clear strategy or faces immediate challenges.
Why it matters: Changes in leadership can change company plans. This affects future growth and work.
Watch forLook for positive changes or plans from the new CEO, James Sapirstein.
Also watch forNo big changes or ongoing problems under the new CEO's leadership.
Why it matters: Topline data will show if the lead drug, CDI-988, is effective. This is crucial for Cocrystal's future.
Supportive ifTopline data from the Phase 1b norovirus trial is reported by the end of 2026-Q4.
Worry ifData is delayed beyond the end of 2026-Q4 or shows no efficacy.